Skip to content

News & calendar

news: as of 2026-10-10
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Thu · 16 Jul

earnings

00:04
Google News: Insilico Medicine

Insilico revenue soars above $100 million on AI drug partnerships

Insilico Medicine's revenue surpassed $100 million, driven by its AI drug-discovery partnerships.

Markets open original ↗

regulation

00:00
Merck

Merck's LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C

The U.S. FDA approved Merck's LIPFENDRA (enlicitide), the first and only once-daily oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH. In the Phase 3 CORALreef program, LIPFENDRA reduced LDL-C by 56% at week 24 in CORALreef Lipids and by 59% in CORALreef HeFH versus placebo.

Markets open original ↗

Wed · 15 Jul

product

23:55
Google News: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech's Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

Kelun-Biotech's Sac-TMT–Keytruda combination outperformed standard first-line therapy in a Phase III lung cancer trial.

Markets open original ↗

earnings

23:38
Google News: Southern Company

SOJD Q1 2026 Earnings: Southern Company Beats EPS Estimates with 5.91% Surprise, Bond Prices Edge Higher

Southern Company beat Q1 2026 EPS estimates by a 5.91% surprise.

Markets open original ↗

personnel

23:32
Google News: American Airlines Group Inc.

Former FedEx CFO John Dietrich joins American Airlines board

Former FedEx CFO John Dietrich has joined American Airlines' board of directors.

Markets open original ↗

The wire

everything that arrived · 7 days